LIDDS AB (LIDDS) Stock Overview

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. The company's oncology pipeline in clinical development includes Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug that binds and blocks androgen receptors; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological conditions, such as breast cancer, head and neck cancer, and prostate cancer; and Nanoimod, a NanoZolid-formulated agatolimod, which is a toll-like receptor 9 (TLR9) agonist. The company was founded in 2003 and is based in Uppsala, Sweden.